This review summarises the clinical activity of T-DM1 in the treatment of HER2-positive breast cancer, outlines the multiple mechanisms of action of T-DM1 and describes various resistance mechanisms that relate to the actions of T-DM1. This evidence concerns the gene ERBB2 and breast carcinoma.